Hepatitis Monthly

Published by: Kowsar

Immune Responses of Mice Immunized with HBsAg Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine

Shima Nejati 1 , Sahar Mirzaee 2 , Hamid Reza Nouri 3 , Ramin Farhoudi 4 , Nabi Allah Namvar 4 , Mohammad Hossein Yazdi 5 , 6 , * and Mehdi Mahdavi 7 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran
2 Department of Biotechnology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran (IAUPS)
3 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 Laboratory Animal Science Department, Pasteur Institute of Iran, Karaj, Iran
5 Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
6 Evidence-Based Medicine Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
7 Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: March 2017, 17 (3); e44536
  • Published Online: March 12, 2017
  • Article Type: Research Article
  • Received: December 5, 2016
  • Revised: February 2, 2017
  • Accepted: March 6, 2017
  • DOI: 10.5812/hepatmon.44536

To Cite: Nejati S, Mirzaee S, Nouri H R, Farhoudi R, Namvar N A, et al. Immune Responses of Mice Immunized with HBsAg Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine, Hepat Mon. 2017 ;17(3):e44536. doi: 10.5812/hepatmon.44536.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Aiyer-Harini P, Ashok-Kumar HG, Kumar GP, Shivakumar N. An overview of immunologic adjuvants-A review. J Vaccines Vaccin. 2013; 4(1): 1-4[DOI]
  • 2. Budai J. [The role of vaccination in the prevention of communicable diseases]. Orv Hetil. 1998; 139(46): 2755-9[PubMed]
  • 3. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014; 6(6): 708-20[DOI][PubMed]
  • 4. Madalinski K, Kolakowska A, Godzik P. Current views on the persistence of immunity following hepatitis B vaccination. Przegl Epidemiol. 2015; 69(1): 47-51[PubMed]
  • 5. Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol. 2013; 3(4): 301-12[DOI][PubMed]
  • 6. Orenbuch-Harroch E, Levy L, Ben-Chetrit E. Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question. World J Gastroenterol. 2008; 14(46): 7133-7[PubMed]
  • 7. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32(3): 635-9[DOI][PubMed]
  • 8. Nakayama T. [Influenza vaccine and adjuvant]. Yakugaku Zasshi. 2011; 131(12): 1723-31[PubMed]
  • 9. Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S. Vaccine Potentiation by Combination Adjuvants. Vaccines (Basel). 2014; 2(2): 297-322[DOI][PubMed]
  • 10. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014; 111(34): 12294-9[DOI][PubMed]
  • 11. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013; 138(5): 779-95[PubMed]
  • 12. Kashiwagi S, Brauns T, Gelfand J, Poznansky MC. Laser vaccine adjuvants. History, progress, and potential. Hum Vaccin Immunother. 2014; 10(7): 1892-907[DOI][PubMed]
  • 13. Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011; 10(4): 523-37[DOI][PubMed]
  • 14. Fathi M, Nezamzadeh R, Mahdavi M. Studying the effects of Naloxone-Alum adjuvant mixture on cytokines in model of multi-epitope vaccine in HIV-1. J Chem Health Risks. 2014; 4(2): 7-14
  • 15. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009; 30(1): 23-32[DOI][PubMed]
  • 16. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol. 2009; 21(3): 217-25[DOI][PubMed]
  • 17. Aghasadeghi MR, Banifazl M, Aghakhani A, Eslamifar A, Vahabpour R, Ramezani A. No evidence for occult HBV infection in hepatitis B vaccine non-responders. Iran J Microbiol. 2014; 6(5): 350-3[PubMed]
  • 18. Tong NK, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005; 68(5): 2298-303[DOI][PubMed]
  • 19. Beran J, Hobzova L, Wertzova V, Kuriyakose S, Leyssen M, Surquin M, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010; 6(7): 578-84[DOI][PubMed]
  • 20. Jazani NH, Parsania S, Sohrabpour M, Mazloomi E, Karimzad M, Shahabi S. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology. 2011; 216(6): 744-51[DOI][PubMed]
  • 21. Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010; 112(6): 1417-27[DOI][PubMed]
  • 22. Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol. 2011; 61(1): 54-62[DOI][PubMed]
  • 23. Jazani NH, Karimzad M, Mazloomi E, Sohrabpour M, Hassan ZM, Ghasemnejad H, et al. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect. 2010; 12(5): 382-8[DOI][PubMed]
  • 24. Sacerdote P, di San Secondo VE, Sirchia G, Manfredi B, Panerai AE. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol. 1998; 113(3): 465-9[DOI][PubMed]
  • 25. Sacerdote P, Gaspani L, Panerai AE. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann N Y Acad Sci. 2000; 917: 755-63[PubMed]
  • 26. Motaharinia Y, Rezaee MA, Rashidi A, Jalili A, Rezaie MJ, Shapouri R, et al. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M. J Microbiol Immunol Infect. 2013; 46(4): 253-8[DOI][PubMed]
  • 27. Jamali A, Mahdavi M, Shahabi S, Hassan ZM, Sabahi F, Javan M, et al. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathog. 2007; 43(5-6): 217-23[DOI][PubMed]
  • 28. Gherardi RK, Eidi H, Crepeaux G, Authier FJ, Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015; 6: 4[DOI][PubMed]
  • 29. Dezfuli HT, Shahbazzadeh D, Eidi A, Bagheri KP, Pakravan N, Amini S, et al. Induction of IFN-gamma cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench. 2014; 7(2): 108-17[PubMed]
  • 30. Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2): 320-43[DOI][PubMed]
  • 31. Jahangiri S, Abtahi Froushani SM, Delirezh N. Combination immunotherapy with extract of heated 4T1 and naloxone in mouse model of breast cancer. Turk J Med Sci. 2016; 46(2): 518-23[DOI][PubMed]
  • 32. Mazloomi E, Jazani NH, Shahabi S. A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. Vaccine. 2012; 30(16): 2640-6[DOI][PubMed]
  • 33. Jafarzadeh A, Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin Exp Immunol. 2003; 131(3): 451-6[DOI][PubMed]
  • 34. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology. 2004; 326(1): 20-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader